ReviewBioengineering (Basel, Switzerland)2025
Tinkering with Blood: Optimizing the Coagulation System for Therapeutic Purposes.
Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood is a multitask, fluid tissue that is considered as an endless goldmine for regenerative therapies. This connective tissue carries myriad multidomain proteins as the workhorse of biological functions integrated in complex molecular networks. Among them, the coagulation system stands out, with platelets and plasma coagulation proteins playing multiple roles in clotting, defense and tissue repair, the latter of which is the final byproduct process stemming from the hemostatic-inflammatory, cell-reprogramming and inflammation resolution after a tissue injury. By mimicking coagulation and hemostasis but lacking inflammatory properties, platelet-rich plasma (PRP) is emerging as an innovative autologous therapy operating as a local delivery system of growth factors. Processing of the patient blood to manufacture PRP encompasses blood anticoagulation; blood deconstruction through centrifugation and fractionation; and activation of plasma, endowing the applied product with anti-inflammatory, trophic, antifibrotic and antialgic properties in a context-dependent manner. However, the field of PRPs faces controversies due to the heterogeneity of their biological compositions and modalities of application. Moreover, there are some drawbacks derived from patient age and some other conditions, all impinging negatively on PRP clinical outcomes. Standardization of the manufacturing process, elaboration of guidelines of application and use of allogenic PRPs are emerging as possible solutions to surmount these pitfalls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.